Merck & Co., Inc. (MRK) Scheduled to Post Quarterly Earnings on Tuesday

Merck & Co., Inc. (NYSE:MRK) is set to release its earnings data before the market opens on Tuesday, July 30th. Analysts expect Merck & Co., Inc. to post earnings of $2.14 per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.40 earnings per share. On average, analysts expect Merck & Co., Inc. to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $125.26 on Monday. The firm has a market cap of $317.26 billion, a price-to-earnings ratio of 139.18, a PEG ratio of 1.63 and a beta of 0.38. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $134.63. The company has a 50 day moving average of $128.12 and a 200-day moving average of $126.61.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Monday, September 16th. This represents a $3.08 dividend on an annualized basis and a yield of 2.46%. Merck & Co., Inc.’s dividend payout ratio is 342.22%.

Analysts Set New Price Targets

MRK has been the topic of several research reports. Berenberg Bank upped their price target on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Truist Financial boosted their price objective on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price target on shares of Merck & Co., Inc. in a report on Tuesday, June 18th. Finally, Morgan Stanley boosted their price objective on Merck & Co., Inc. from $132.00 to $134.00 and gave the stock an “equal weight” rating in a report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus price target of $135.36.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.